DK3288944T3 - Imidazopyrazinoner som pde1-inhibitorer - Google Patents

Imidazopyrazinoner som pde1-inhibitorer Download PDF

Info

Publication number
DK3288944T3
DK3288944T3 DK16720101.1T DK16720101T DK3288944T3 DK 3288944 T3 DK3288944 T3 DK 3288944T3 DK 16720101 T DK16720101 T DK 16720101T DK 3288944 T3 DK3288944 T3 DK 3288944T3
Authority
DK
Denmark
Prior art keywords
imidazopyrazinones
pde1 inhibitors
pde1
inhibitors
Prior art date
Application number
DK16720101.1T
Other languages
English (en)
Inventor
Mikkel Jessing
Karsten Juhl
Morten Langgård
Paulo Jorge Vieira Vital
Jan Kehler
Lars Kyhn Rasmussen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3288944T3 publication Critical patent/DK3288944T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16720101.1T 2015-04-30 2016-04-29 Imidazopyrazinoner som pde1-inhibitorer DK3288944T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
PCT/EP2016/059583 WO2016174188A1 (en) 2015-04-30 2016-04-29 Imidazopyrazinones as pde1 inhibitors

Publications (1)

Publication Number Publication Date
DK3288944T3 true DK3288944T3 (da) 2019-07-22

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16720101.1T DK3288944T3 (da) 2015-04-30 2016-04-29 Imidazopyrazinoner som pde1-inhibitorer

Country Status (41)

Country Link
US (4) US20160318939A1 (da)
EP (1) EP3288944B1 (da)
JP (1) JP6663930B2 (da)
KR (1) KR102605759B1 (da)
CN (1) CN107531714B (da)
AU (1) AU2016256573B2 (da)
BR (1) BR112017023182B1 (da)
CA (1) CA2983563A1 (da)
CL (1) CL2017002719A1 (da)
CO (1) CO2017010399A2 (da)
CY (1) CY1121806T1 (da)
DK (1) DK3288944T3 (da)
DO (1) DOP2017000254A (da)
EA (1) EA031946B1 (da)
EC (1) ECSP17072228A (da)
ES (1) ES2735422T3 (da)
GE (1) GEP20207058B (da)
GT (1) GT201700223A (da)
HK (1) HK1252098B (da)
HR (1) HRP20191180T1 (da)
HU (1) HUE044244T2 (da)
IL (1) IL255316B (da)
JO (1) JO3627B1 (da)
LT (1) LT3288944T (da)
MA (1) MA41977B1 (da)
ME (1) ME03414B (da)
MX (1) MX2017013785A (da)
MY (1) MY182382A (da)
PE (1) PE20180121A1 (da)
PH (1) PH12017501990A1 (da)
PL (1) PL3288944T3 (da)
PT (1) PT3288944T (da)
RS (1) RS59051B1 (da)
RU (1) RU2712219C2 (da)
SG (1) SG11201708822PA (da)
SI (1) SI3288944T1 (da)
TN (1) TN2017000428A1 (da)
TW (1) TWI695838B (da)
UA (1) UA123050C2 (da)
WO (1) WO2016174188A1 (da)
ZA (1) ZA201706847B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
MX2019004763A (es) * 2016-10-28 2019-07-01 H Lundbeck As Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
MX2019007803A (es) 2016-12-28 2019-08-29 Dart Neuroscience Llc Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン
WO2024121046A1 (en) * 2022-12-05 2024-06-13 Angelini Pharma S.P.A. Amide compounds as activators of the potassium channels kv7.2/kv7.3 useful in the treatment of cns and pns disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
EP1626971B1 (de) 2003-05-09 2011-08-10 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
AP2139A (en) * 2004-04-02 2010-08-21 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
EP1828192B1 (en) * 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
SI2152712T1 (sl) 2007-05-11 2012-03-30 Pfizer Amino heterociklične spojine
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
EA201170772A1 (ru) * 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EA032675B1 (ru) 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
PT3339323T (pt) 2010-08-12 2020-01-14 Lilly Co Eli Anticorpos anti-péptido beta-amilóide n3pglu e seus usos
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
CN106905324B (zh) * 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
BR112014031730B1 (pt) 2012-06-18 2023-05-16 Dart Neuroscience (Cayman) Ltd Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso
RU2679142C2 (ru) 2013-03-15 2019-02-06 Интра-Селлулар Терапиз, Инк. Органические соединения
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
GEP20186892B (en) 2014-02-19 2018-09-10 Lundbeck A/S H 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
JP2017527606A (ja) 2014-09-18 2017-09-21 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 三環系誘導体
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
TW201639851A (zh) 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EA201890256A1 (ru) 2015-08-12 2018-06-29 Х. Лундбекк А/С 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
MX2019004763A (es) 2016-10-28 2019-07-01 H Lundbeck As Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones

Also Published As

Publication number Publication date
JO3627B1 (ar) 2020-08-27
AU2016256573B2 (en) 2019-11-21
CN107531714A (zh) 2018-01-02
SI3288944T1 (sl) 2019-08-30
CA2983563A1 (en) 2016-11-03
BR112017023182B1 (pt) 2023-10-31
IL255316B (en) 2021-10-31
EP3288944A1 (en) 2018-03-07
TW201700477A (zh) 2017-01-01
CO2017010399A2 (es) 2018-01-05
MY182382A (en) 2021-01-22
HRP20191180T1 (hr) 2019-10-04
US20190062335A1 (en) 2019-02-28
US20160318939A1 (en) 2016-11-03
TN2017000428A1 (en) 2019-04-12
US10011606B2 (en) 2018-07-03
WO2016174188A1 (en) 2016-11-03
EA201792157A1 (ru) 2018-03-30
CY1121806T1 (el) 2020-07-31
US11472810B2 (en) 2022-10-18
SG11201708822PA (en) 2017-11-29
ES2735422T3 (es) 2019-12-18
PH12017501990B1 (en) 2018-03-26
MX2017013785A (es) 2018-03-27
TWI695838B (zh) 2020-06-11
KR102605759B1 (ko) 2023-11-23
US10858362B2 (en) 2020-12-08
RS59051B1 (sr) 2019-08-30
RU2017137514A (ru) 2019-05-31
DOP2017000254A (es) 2018-01-15
PH12017501990A1 (en) 2018-03-26
IL255316A0 (en) 2017-12-31
US20170291903A1 (en) 2017-10-12
BR112017023182A2 (da) 2018-10-02
UA123050C2 (uk) 2021-02-10
KR20170140216A (ko) 2017-12-20
EA031946B1 (ru) 2019-03-29
LT3288944T (lt) 2019-07-25
RU2712219C2 (ru) 2020-01-27
GT201700223A (es) 2018-12-19
CN107531714B (zh) 2019-07-19
US20210238182A1 (en) 2021-08-05
ECSP17072228A (es) 2018-02-28
JP2018514552A (ja) 2018-06-07
MA41977B1 (fr) 2019-08-30
HUE044244T2 (hu) 2019-10-28
PT3288944T (pt) 2019-07-19
HK1252098B (zh) 2020-02-07
ME03414B (me) 2020-01-20
AU2016256573A1 (en) 2017-12-14
JP6663930B2 (ja) 2020-03-13
MA41977A (fr) 2018-07-23
RU2017137514A3 (da) 2019-07-17
GEP20207058B (en) 2020-01-27
EP3288944B1 (en) 2019-06-12
ZA201706847B (en) 2019-01-30
PE20180121A1 (es) 2018-01-18
HK1252098A1 (zh) 2019-05-17
CL2017002719A1 (es) 2018-04-20
PL3288944T3 (pl) 2019-11-29

Similar Documents

Publication Publication Date Title
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3305788T3 (da) Janus-kinase-hæmmer
DK3072835T3 (da) Fremgangsmåde til fremføring
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3277719T3 (da) Polypeptider
MA44006A (fr) Inhibiteur pde1
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3310450T3 (da) Olie-vand-separator
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3341379T3 (da) EZH2-hæmmere
DK3256462T3 (da) Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3270930T3 (da) Præeklampsi
DK3296597T3 (da) Krydshovedmotor
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3265394T3 (da) Fremgangsmåde til emballering